Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

被引:2
|
作者
Sun, Dongxu [1 ]
Rubio-Aparicio, Debora [1 ]
Nelson, Kirk [1 ]
Dudley, Michael N. [1 ]
Lomovskaya, Olga [1 ]
机构
[1] Med Co, San Diego, CA 07054 USA
关键词
vaborbactam; Klebsiella pneumoniae carbapenemases; KPC; resistance development; single-step mutants; BETA-LACTAMASE INHIBITOR; SEQUENCE TYPE 258; CARBAPENEM RESISTANCE; CEFTAZIDIME-AVIBACTAM; ENTEROBACTERIACEAE; RPX7009; SUSCEPTIBILITY; GENE; MUTATIONS; STRAINS;
D O I
10.1128/AAC.01694-17
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Klebsiella pneumoniae carbapenemases (KPC). It has been developed in combination with meropenem. The objective of these studies was to identify the concentrations of both agents associated with the selection or prevention of single-step mutations leading to reduced sensitivity to the combination and to characterize the selected mutations. Eighteen strains of KPC-producing Klebsiella pneumoniae with various degrees of sensitivity to meropenem (MICs, 8 to 512 mu g/ml) and meropenem-vaborbactam (MICs, <= 0.06 to 32 mu g/ml) and preexisting resistance mechanisms were selected from a worldwide collection of isolates recovered from surveillance studies, emphasizing strains for which MICs were in the upper range of the meropenem-vaborbactam MIC distribution. Meropenem and vabor-bactam at 8 mu g/ml each suppressed the drug resistance mutation frequency to <1 X 10(-8) in 77.8% (14/18) of strains, and all strains were inhibited when the meropenem concentration was increased to 16 mu g/ml. Mutants selected at lower drug concentrations showed phenotypes associated with previously described carbapenem resistance mechanisms, including ompK36 inactivation in mutants selected from OmpK36-proficient strains and an increased bla(KPC) gene copy number in strains with partially functional ompK36. No mutations in the coding region of bla(KPC) were identified. These data indicate that the selection of mutants with reduced sensitivity to meropenem-vaborbactam from KPC-producing Klebsiella pneumoniae strains is associated with previously described mechanisms involving porin mutations and the increase in the bla(KPC) gene copy number and not changes in the KPC enzyme and can be prevented by the drug concentrations achieved with optimal dosing of the combination.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Photodynamic inactivation of KPC-producing Klebsiella pneumoniae difficult-to-treat resistance (DTR) by a cationic porphyrin
    de Freitas, Alysson Benite
    Rezende, Hanstter Hallison Alves
    de Souza, Guilherme Rocha Lino
    Goncalves, Pablo Jose
    JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2025, 265
  • [42] Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran
    Amereh, Samira
    Kelishomi, Fatemeh Zeynali
    Ghayaz, Fatemeh
    Javadi, Amir
    Peymani, Amir
    Fardsanei, Fatemeh
    Aali, Ehsan
    Nikkhahi, Farhad
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2022, 69 (03) : 201 - 208
  • [43] Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae
    Zheng, Mei
    Li, Fu-Hao
    Liu, Juan
    Li, Wen-Jie
    Yin, Ruo-Xi
    Cai, Da-Tong
    Andrey, Diego O.
    Zheng, Si-Lin
    Gales, Ana C.
    Zhang, Wan-Jiang
    Sun, Jian
    Liao, Xiao-Ping
    Yu, Yang
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1069 - 1080
  • [44] Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti, Piergiorgio
    Sartor, Assunta
    Bassetti, Matteo
    Scarparo, Claudio
    Pea, Federico
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 14 : 233 - 236
  • [45] Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae
    Rogers, Tara M.
    Kline, Ellen G.
    Griffith, Marissa P.
    Jones, Chelsea E.
    Rubio, Abigail M.
    Squires, Kevin M.
    Shields, Ryan K.
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (05):
  • [46] Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series
    van Asten, S. A., V
    Boattini, M.
    Kraakman, M. E. M.
    Bianco, G.
    Iannaccone, M.
    Costa, C.
    Cavallo, R.
    Bernards, A. T.
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (05) : 778 - 780
  • [47] Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing Klebsiella pneumoniae
    Polani, Riccardo
    De Francesco, Alice
    Tomolillo, Dario
    Artuso, Irene
    Equestre, Michele
    Trirocco, Rita
    Arcari, Gabriele
    Antonelli, Guido
    Villa, Laura
    Prosseda, Gianni
    Visca, Paolo
    Carattoli, Alessandra
    EMERGING INFECTIOUS DISEASES, 2025, 31 (01) : 123 - 134
  • [48] Stress-Adaptive Responses Associated with High-Level Carbapenem Resistance in KPC-Producing Klebsiella pneumoniae
    Adams-Sapper, Sheila
    Gayoso, Adam
    Riley, Lee. W.
    JOURNAL OF PATHOGENS, 2018, 2018
  • [49] Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae
    Diep, John K.
    Jacobs, David M.
    Sharma, Rajnikant
    Covelli, Jenna
    Bowers, Dana R.
    Russo, Thomas A.
    Rao, Gauri G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)
  • [50] A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia
    Gatti, Milo
    Rinaldi, Matteo
    Gaibani, Paolo
    Siniscalchi, Antonio
    Tonetti, Tommaso
    Viale, Pierluigi
    Pea, Federico
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (05)